HAIXI PHARMA Maintains 78.71 Million Issued Shares in March 2026; Public Float Meets 25% Threshold

Bulletin Express04-08

Fujian Haixi Pharmaceuticals Co., Ltd. (HAIXI PHARMA) filed its Monthly Return to Hong Kong Exchanges and Clearing for the period ended 31 March 2026, confirming no changes in either authorised or issued share capital during the month.

1. Authorised / Registered Share Capital • Class: H-share ordinary shares • Par value: RMB 1.00 per share • Balance at 29 February 2026 and 31 March 2026: 78.71 million shares, representing RMB 78.71 million registered capital.

2. Issued Share Capital and Treasury Shares • Outstanding shares: 78.71 million • Treasury shares: 0 • Net change in March 2026: 0

3. Public Float Status HAIXI PHARMA confirmed compliance with the Main Board initial prescribed public-float threshold of 25% of issued H-shares as at 31 March 2026.

4. Corporate Actions No share options, warrants, convertible securities, share repurchases, or other equity arrangements were recorded during the month.

The filing, signed by Joint Company Secretary Zhang Junhuan on 8 April 2026, indicates a stable capital structure with full adherence to Hong Kong Listing Rule requirements.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1112407237?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-08 17:04","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1112407237","market":"hk","top_or_hot":-1,"title":"HAIXI PHARMA Maintains 78.71 Million Issued Shares in March 2026; Public Float Meets 25% Threshold","media":"Bulletin Express","content":"<p>Fujian Haixi Pharmaceuticals Co., Ltd. (HAIXI PHARMA) filed its Monthly Return to Hong Kong Exchanges and Clearing for the period ended 31 March 2026, confirming no changes in either authorised or issued share capital during the month.</p>\n\n<p>1. Authorised / Registered Share Capital  \n• Class: H-share ordinary shares  \n• Par value: RMB 1.00 per share  \n• Balance at 29 February 2026 and 31 March 2026: 78.71 million shares, representing RMB 78.71 million registered capital.</p>\n\n<p>2. Issued Share Capital and Treasury Shares  \n• Outstanding shares: 78.71 million  \n• Treasury shares: 0  \n• Net change in March 2026: 0</p>\n\n<p>3. Public Float Status  \nHAIXI PHARMA confirmed compliance with the Main Board initial prescribed public-float threshold of 25% of issued H-shares as at 31 March 2026.</p>\n\n<p>4. Corporate Actions  \nNo share options, warrants, convertible securities, share repurchases, or other equity arrangements were recorded during the month.</p>\n\n<p>The filing, signed by Joint Company Secretary Zhang Junhuan on 8 April 2026, indicates a stable capital structure with full adherence to Hong Kong Listing Rule requirements.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>HAIXI PHARMA Maintains 78.71 Million Issued Shares in March 2026; Public Float Meets 25% Threshold</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHAIXI PHARMA Maintains 78.71 Million Issued Shares in March 2026; Public Float Meets 25% Threshold\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-04-08 17:04</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Fujian Haixi Pharmaceuticals Co., Ltd. (HAIXI PHARMA) filed its Monthly Return to Hong Kong Exchanges and Clearing for the period ended 31 March 2026, confirming no changes in either authorised or issued share capital during the month.</p>\n\n<p>1. Authorised / Registered Share Capital  \n• Class: H-share ordinary shares  \n• Par value: RMB 1.00 per share  \n• Balance at 29 February 2026 and 31 March 2026: 78.71 million shares, representing RMB 78.71 million registered capital.</p>\n\n<p>2. Issued Share Capital and Treasury Shares  \n• Outstanding shares: 78.71 million  \n• Treasury shares: 0  \n• Net change in March 2026: 0</p>\n\n<p>3. Public Float Status  \nHAIXI PHARMA confirmed compliance with the Main Board initial prescribed public-float threshold of 25% of issued H-shares as at 31 March 2026.</p>\n\n<p>4. Corporate Actions  \nNo share options, warrants, convertible securities, share repurchases, or other equity arrangements were recorded during the month.</p>\n\n<p>The filing, signed by Joint Company Secretary Zhang Junhuan on 8 April 2026, indicates a stable capital structure with full adherence to Hong Kong Listing Rule requirements.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02637","symbol_name":"海西新药","start_time":0,"source_url":"","article_id":"1112407237","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1112407237","pubTimestamp":1775639074,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Fujian Haixi Pharmaceuticals Co., Ltd. (HAIXI PHARMA) filed its Monthly Return to Hong Kong Exchanges and Clearing for the period ended 31 March 2026, confirming no changes in either authorised or...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02637":"海西新药"},"translate_title":"海西药业2026年3月维持7871万股已发行股份；公众持股量达到25%门槛","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02637":1},"content_text":"Fujian Haixi Pharmaceuticals Co., Ltd. (HAIXI PHARMA) filed its Monthly Return to Hong Kong Exchanges and Clearing for the period ended 31 March 2026, confirming no changes in either authorised or issued share capital during the month.\n1. Authorised / Registered Share Capital  \n• Class: H-share ordinary shares  \n• Par value: RMB 1.00 per share  \n• Balance at 29 February 2026 and 31 March 2026: 78.71 million shares, representing RMB 78.71 million registered capital.\n2. Issued Share Capital and Treasury Shares  \n• Outstanding shares: 78.71 million  \n• Treasury shares: 0  \n• Net change in March 2026: 0\n3. Public Float Status  \nHAIXI PHARMA confirmed compliance with the Main Board initial prescribed public-float threshold of 25% of issued H-shares as at 31 March 2026.\n4. Corporate Actions  \nNo share options, warrants, convertible securities, share repurchases, or other equity arrangements were recorded during the month.\nThe filing, signed by Joint Company Secretary Zhang Junhuan on 8 April 2026, indicates a stable capital structure with full adherence to Hong Kong Listing Rule requirements.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1112407237","isCrawlerRequest":true}